Triple

T18213149
Position Surface form Disambiguated ID Type / Status
Subject vincristine E436082 entity
Predicate usedInRegimen P25490 FINISHED
Object CHOP chemotherapy regimen NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CHOP chemotherapy regimen | Statement: [vincristine, usedInRegimen, CHOP chemotherapy regimen]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: CHOP chemotherapy regimen
Context triple: [vincristine, usedInRegimen, CHOP chemotherapy regimen]
  • A. BEACOPP regimen
    The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
  • B. R-CHOP chosen
    R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
  • C. ABVD regimen
    The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
  • D. FOLFIRI regimen
    The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
  • E. cyclophosphamide
    Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: usedInRegimen
Context triple: [vincristine, usedInRegimen, CHOP chemotherapy regimen]
  • A. usesDrug
    Indicates that an entity consumes, administers, or otherwise makes use of a specified drug.
  • B. areUsedIn chosen
    Indicates that certain entities serve as components, tools, or resources within a particular process, context, or application.
  • C. hasDosingRegimen
    Indicates that an entity is associated with a specific dosing regimen, defining how and when a dose is to be administered.
  • D. isIndicatedAsMonotherapyFor
    Indicates that a treatment is recommended or used alone, without combination with other therapies, for a particular condition or purpose.
  • E. usesTreatment
    Indicates that one entity applies or employs a particular treatment or therapeutic method on or for another entity.
  • F. None of above.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8b90dba6481908e119eb9aa4ca0cb completed April 10, 2026, 8:47 a.m.
NER Named-entity recognition batch_69e4e22a26308190a6720b41a9bbfc2d completed April 19, 2026, 2:09 p.m.
PD Predicate disambiguation batch_69e4332155d88190b106d0dceb4554af completed April 19, 2026, 1:42 a.m.
Created at: April 10, 2026, 10:32 a.m.